Basic study of anti-CD3 X anti-tumor bispecific antibody therapy using helper/killer cells for malignant hemangioentothelioma.

使用辅助/杀伤细胞进行抗 CD3 X 抗肿瘤双特异性抗体治疗恶性血管内皮瘤的基础研究。

• 批准号: 05670743
• 负责人: MASUZAWA Mikio
• 金额: $ 1.22万
• 依托单位: Kitasato University School of Medicine
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for General Scientific Research (C)
• 财政年份: 1993
• 资助国家: 日本
• 起止时间: 1993 至 1994
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/en/grant/KAKENHI-PROJECT-05670743/
• 关键词: Malignant hemangioendo-thwlioma; bispecific antibody; helper; killer cells; rIL-2; LAK; adoptive immunotherapy; 悪性血管内皮細胞; ペルパー; キラー

LAK adoptive immunotherapy is recognized as the one and the only effective therapy for malignant hemangioendothelioma (MHE) that is an extremely fatal neoplasm. To advance this therapy, we examined basic studies of bispecific antibody (Ab) therapy using helper/killer cells.We established a human malignant endothelial cell line (ISO-HAS) as tumor antigen (Ag) to make monoclonal antibody (monoAb) and as target cell for cytotoxic assay. It was derived from MHE arising on the scalp and expressed several oncogenes and mutated suppessive oncogenes. Using ISO-HAS,we obtained some Abs responsive to both ISO-HAS and normal endothelial cells (EC), but no specific Ab against ISO-HAS.CD4^+T cells were separated from PBMC by magnetic cell separation system (MACS). We cultured CD4^+killer cells by bi-stimulation of rIL-2 and anti-CD3 Ab. Discontinuous stimulation by immobilized anti-CD3 Ab was needed to culture them massively. By RT-PCR methods, we observed the expression of mRNA of IL-2 and gamma IFN in CD4^+killer cells. These cells alone showed about 70% cytotoxicity against ISO-HAS in high E/T ratio (100/1).Our results suggested that tumor-specific Ag of MHE is too weak to make a monoAb. Moreover, to show high cytotoxic activity in low E/T ratio, CD4^+killer cells need a bridging Ab to make contact with tumor cells. Therefore, we are now making a bispecific Ab using ABs to CD3 and CD31 which is preserved on MHE as well as normal EC.We will present the final report including the results of our studies using this bispecific Ab.

LAK过继免疫治疗是目前公认的治疗恶性血管内皮瘤（MHE）的唯一有效方法。为了推进这种治疗，我们研究了使用辅助/杀伤细胞的双特异性抗体（Ab）治疗的基础研究。我们建立了人恶性内皮细胞系（ISO-HAS）作为肿瘤抗原（Ag）制备单克隆抗体（monoAb），并作为细胞毒性试验的靶细胞。它来源于头皮上产生的MHE，表达了几种致癌基因和突变的抑制性致癌基因。使用ISO-HAS，我们获得了一些对ISO-HAS和正常内皮细胞（EC）都有反应的抗体，但没有针对ISO-HAS的特异性抗体。采用磁性细胞分离系统（MACS）分离CD4^+T细胞。我们通过il -2和抗cd3抗体双刺激培养CD4^+杀伤细胞，需要固定化抗cd3抗体间断刺激才能大规模培养CD4^+杀伤细胞。采用RT-PCR方法观察CD4^+杀伤细胞中IL-2和γ - IFN mRNA的表达。这些细胞在高E/T比（100/1）下对ISO-HAS表现出约70%的细胞毒性。我们的结果表明，MHE的肿瘤特异性Ag太弱，无法产生单抗。此外，为了在低E/T比下显示高的细胞毒活性，CD4^+杀伤细胞需要桥接Ab才能与肿瘤细胞接触。因此，我们现在使用抗体来制造双特异性抗体，CD3和CD31保存在MHE和正常EC上。我们将提交最终报告，包括我们使用这种双特异性抗体的研究结果。